Adherex Technologies, Inc.
10
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
20.0%
2 terminated/withdrawn out of 10 trials
75.0%
-11.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer
Role: collaborator
Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer
Role: lead
A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan
Role: lead
A Study of ADH 1 in Combination With Carboplatin, or Docetaxel or Capecitabine
Role: lead
Study of ADH-1 Given Intravenously to Patients With Solid Tumors
Role: lead
A Study of 5 Fluorouracil and the Anti-Tumor Activity of ADH300004 and 5 Fluorouracil in Subjects With Incurable Solid Tumors
Role: lead
A Study of ADH300004 and 5-Fluorouracil in Locally Advanced, Recurrent, or Metastatic Hepatocellular Carcinoma
Role: lead
A Study of the Safety and Effects of ADH-1 Given Daily to Subjects With Solid Tumors
Role: lead
A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent
Role: lead
A Study of ADH300004 in Surgically Resected Primary or Metastatic Colorectal Cancer and Liver Biopsy, or Planned Hepatic Resection
Role: lead
All 10 trials loaded